



pharmaceuticals ltd.

Regd.&Corporate Office :
Plot No. 19-111, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills Hyderabad - 500 096. A.P. INDIA,
Tel : +91-40-6628 8888, Fax : +91-40-2355 1401

CIN : L24239AP1937PLC008996

Email : info@smspharma.com

www.smspharma.com

By Mail/Courier

August 12, 2014.

Stock Code : BSE: 532815
Bombay Stock Exchange Limited
Corporate Relationship Department
2nd Floor, New Trading Wing
Dalal Street, Mumbai-400 001.

NSE : SMSPHARMA
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor, Plot No.C/1
G Block, Bandra-Kurla Complex
Bandra (E), Mumbai-400 051.

Dear Sir,

Sub: Out-come of the Board Meeting held on 12.08.2014.

We hereby inform that the Board has taken the following decisions in its meeting held on 12.08.2014.


1. Appointed Mr. P. Sarath Kumar as an Additional Director.
2. Appointed Dr.(Mrs.) Thummala Neelaveni as an Additional Director.
3. Approved the Un-audited Financial Results for the quarter ended 30th June, 2014 along with Limited Review Report, a copy of the same is enclosed herewith.
4. Constituted the Corporate Social Responsibility Committee (CSR Committee).
5. The Board considered and re-renamed and re-constituted the existing following Committees ;

S. No.	Name of Existing Committee	Re-Named as
01.	Investors Grievance Committee	Stakeholders Relationship Committee
02.	Remuneration Committee	Nomination and Remuneration Committee

Please take the same on your records.


By order of the Board.
SMS Pharmaceuticals Limited


N Rajendra Prasad
Chief Financial Officer



Encl: A/a.

SMS PHARMACEUTICAL LIMITED Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 034 Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2014					
S.No.	Particulars	Quarter Ended			(Rs. In Lacs)
		30-06-2014 (Unaudited)	31-03-2014 (Unaudited)	30-06-2013 (Unaudited)	31-03-2014 Audited
1	Income from Operations				
	(a) Net sales/Income from Operations	12,724.37	14,785.39	8,860.25	48,197.76
	(b) Other Operating Income	1,090.43	1,491.56	138.55	3,606.04
	Total Income from Operations (net)	13,814.79	16,276.95	8,998.80	51,803.80
2	Expenses				
	(a) Cost of materials consumed	9,331.98	10,930.56	6,442.08	34,665.71
	(b) Purchases of stock-in-trade	16.90	4.42	-	4.42
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	353.88	(116.56)	858.45	2,087.02
	(d) Employee Benefits Expense	744.87	792.06	485.82	2,563.93
	(e) Depreciation and amortisation expense	402.97	480.91	266.70	1,285.46
	(f) Other expenses	1,570.23	2,377.53	1,052.63	6,765.98
	Total - (a to f)	12,420.83	14,468.93	9,105.68	47,372.51
3	Profit from Operations before Other Income, finance cost and Exceptional Items (1) - (2)	1,393.97	1,808.02	(106.89)	4,431.28
4	Other Income	26.52	50.99	124.21	152.41
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3)+(4)	1,420.48	1,859.01	17.32	4,583.69
6	Finance costs	404.18	101.01	424.55	1,381.88
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5)-(6)	1,016.31	1,758.00	(407.23)	3,201.81
8	Exceptional items	-	-	-	-
9	Profit / (Loss) from Ordinary Activities before Tax (7)+(8)	1,016.31	1,758.00	(407.23)	3,201.81
10	Tax Expenses	198.00	663.36	-	1,163.36
11	Net Profit / (Loss) from ordinary activities after Tax (9)-(10)	818.31	1,094.64	(407.23)	2,038.45
12	Extraordinary items (net of Tax Expense Rs. ... in lakhs)	-	-	-	-
13	Net Profit / (Loss) for the period (11) -(12)	818.31	1,094.64	(407.23)	2,038.45
14	Share of profit / (loss) of associates*	-	-	-	-
15	Minority Interest*	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	-	-	-	-
17	Paid-up equity share capital Rs.10/- per share	846.52	846.52	869.01	846.52
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-
19.i	Earning Per Share (before extraordinary items) (of Rs.... / each) (not annualised)	9.64	12.93	(4.15)	23.06
19.ii	Earning Per Share (after extraordinary items) (of Rs.... / each) (not annualised)	9.64	12.93	(4.15)	23.06
	(a) Basic				
	(b) Diluted				



A PARTICULARS OF SHARE HOLDING					3 Months ended 30-06-2014	
1	Public Shareholding - Number of Shares - Percentage of Shareholding	3,054,760 36.09	3,054,760 36.09	3,279,637 37.74	3,054,760 36.09	3,054,760 36.09
2	Promoters and Promoters Group Shareholding** a) Pledged/Encumbered - Number of Shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of Shares (as a % of the total share capital of the company) b) Non-encumbered - Number of Shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of Shares (as a % of the total share capital of the company)	- - - - 5,410,443 100 63.91	- - - - 5,410,443 100 63.91	- - - - 5,410,443 100 62.26	- - - - 5,410,443 100 63.91	- - - - 5,410,443 100 63.91
B INVESTOR COMPLAINTS					3 Months ended 30-06-2014	
	Particulars					
	Pending at the beginning of the quarter					Nil
	Received during the quarter					Nil
	Disposed of during the quarter					Nil
	Remaining unresolved at the end of the quarter					Nil
Notes:						
1.	The above results are reviewed by the Audit Committee on 12th August, 2014 and taken on record by the Board of Directors at its meeting held on 12th August, 2014 and "Limited Review" of the same has been carried out by the Statutory Auditors of the Company.					
2	The useful life of fixed assets has been revised in accordance with schedule II of the Companies Act, 2013. On account of change in the useful life, depreciation expenses for the quarter is lower by Rs.4.08 Lakhs					
3	All accounting policies followed are consistent, subject to note no.4					
4	The Company's business activity falls within a single primary business segment. Hence segment reporting is not applicable.					
5	Figures of previous periods have been regrouped / rearranged wherever necessary.					
		For SMS Pharmaceuticals Limited  Ramesh Babu Potluri Chairman & Managing Director				
		Place: Hyderabad Date :12-08-2014				

Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED,
Hyderabad.


We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED for the quarter ended 30th June 2014 except for the disclosures regarding 'public shareholding' and 'promoter Group Shareholding' which has been traced from disclosures made by the management and has not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by Independent Auditor of Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards, within the meaning of Sec.133 of Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad,
Date: 12-08-2014.

For RAMBABU & CO.,
Chartered Accountants
Firm Reg. No. 0029765


GVL PRASAD
Partner
M. No. 26548.

